Ph I Dasatinib + Erlotinib in Recurrent MG

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
GlioblastomaGliosarcoma
Interventions
DRUG

Erlotinib and Dasatinib

You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected \& will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 \& at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib \& Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib \& Erlotinib given daily for 28 days for purpose of scheduling evaluations.

Trial Locations (1)

27710

Duke University Health System, Durham

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Duke University

OTHER